The December 2024 FDA approval of Ryoncil for steroid-refractory acute graft-versus-host disease was not an orthopedic milestone. It was an immune milestone, confirming that the FDA will approve mesenchymal stem cell-based therapies for immune and inflammatory conditions when the Phase 3 evidence supports them. Adipose-derived stem cells share the same core immunomodulatory properties that drove the Ryoncil approval, and active clinical trials are investigating ADSCs in Crohn’s disease, multiple sclerosis, lupus, rheumatoid arthritis, and other inflammatory conditions. This post reviews the biological mechanism, the published evidence, and the active trial pipeline for autoimmune and inflammatory applications of ADSCs, and explains what it means for patients with these conditions who are evaluating banking or trial enrollment.
TLDR: MSC immunomodulation is the mechanism behind the first-ever FDA-approved MSC product (Ryoncil, December 2024, for graft-versus-host disease). ADSCs share these properties. Active clinical trials are investigating ADSCs in Crohn’s disease, multiple sclerosis, lupus, rheumatoid arthritis, and other immune conditions. The evidence base is earlier-stage than orthopedics but growing rapidly. Banking preserves autologous cells for potential access to these pathways. Patients with autoimmune conditions considering banking should act earlier rather than later, as disease progression can affect cell quality.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease, including Crohn’s disease, multiple sclerosis, lupus, rheumatoid arthritis, or any other autoimmune or inflammatory condition. No ADSC-based therapy for these conditions has received FDA approval as of the date of this post. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. The clinical evidence described in this post is from published research and active trials, describing what is being investigated rather than what is proven or approved. All content is for educational purposes only and does not constitute medical advice. Consult your physician before making any healthcare decision.
The December 2024 FDA approval of Ryoncil changed the conversation about MSC-based therapies for immune conditions. Ryoncil is remestemcel-L-rknd, a bone-marrow-derived mesenchymal stem cell product approved for steroid-refractory acute graft-versus-host disease in pediatric patients after a completed Phase 3 randomized trial. It was not approved because MSCs are generally effective for all immune conditions. It was approved because a specific product, in a specific condition, with a specific patient population, completed the Phase 3 evidence standard the FDA requires. That is the same pathway that ADSC-based autoimmune trials are working toward.
For a patient with Crohn’s disease, multiple sclerosis, lupus, or rheumatoid arthritis who has been watching stem cell research for years, the Ryoncil approval is the most concrete proof available that this pathway works. The mechanism is consistent across the category: MSC immunomodulation suppresses the dysregulated immune responses driving disease, reduces inflammatory signaling, and supports tissue repair in the affected organ system. The question is no longer whether MSC immunomodulation is real. Ryoncil established that. The question is when the ADSC-specific trials in these conditions will produce the Phase 3 data needed for their own approvals.
This post covers the immunomodulatory mechanism, the condition-by-condition evidence base, the active trial pipeline, and the specific banking implications for patients with autoimmune conditions.
The Immunomodulatory Mechanism
How ADSCs Modulate the Immune System
Mesenchymal stem cells, including adipose-derived MSCs, exert immunomodulatory effects through four overlapping mechanisms:
- Direct suppression of T-cell and B-cell proliferation. MSCs secrete IDO (indoleamine 2,3-dioxygenase), TGF-beta, and PGE2, which inhibit the proliferation and activation of autoreactive lymphocytes.
- Promotion of regulatory T-cell differentiation. MSCs shift the T-cell balance toward regulatory T cells, which suppress pathological immune responses and help restore immune tolerance.
- Suppression of natural killer cell cytotoxicity. MSCs reduce NK cell activity, which contributes to the broader anti-inflammatory environment at the site of immune dysregulation.
- Macrophage polarization from the M1 pro-inflammatory phenotype to the M2 anti-inflammatory phenotype. This is a key mechanism in chronic inflammatory diseases where persistent M1 macrophage activity drives ongoing tissue damage.
The 2018 MSC clinical review from Galipeau and Sensebe in Cell Stem Cell, the 2019 MSC biology review from Pittenger and colleagues in npj Regenerative Medicine, and the 2006 ISCT minimal criteria from Dominici and colleagues together establish the biological framework these four mechanisms operate within. Save My Fat’s comparison of mesenchymal stem cells across sources puts the ADSC-specific immunomodulatory profile in context against the broader MSC category.
Why ADSCs Are Particularly Well-Suited
ADSCs produce anti-inflammatory secretory factors including HGF, IL-10, and TGF-beta at levels that compare favorably to bone-marrow-derived MSCs in some published comparisons. They are also more accessible. A gram of fat yields 100 to 500 times more mesenchymal stem cells than a gram of bone marrow, as the foundational 2002 Zuk paper established. This yield advantage makes autologous cell banking from adipose tissue more practical than bone marrow harvest for most patients, and the 2013 IFATS and ISCT joint consensus describes the characterization framework used to ensure adipose-derived cells meet the biological criteria the MSC category requires. Save My Fat’s patient-facing introduction to adipose-derived stem cells covers the practical implications of this yield advantage.
The FDA Approval That Changed the Benchmark
Ryoncil: The First MSC Approval
In December 2024, the FDA approved Ryoncil for steroid-refractory acute graft-versus-host disease in pediatric patients two months of age and older. This was the first approval of any MSC-based biologic product by the FDA, and it followed a Phase 3 randomized controlled trial that demonstrated an improvement in overall response rate at Day 28 versus comparator, documented in the FDA’s approved cellular and gene therapy products database.
What the Ryoncil Approval Establishes for ADSC Autoimmune Trials
Three things are now established by this approval. The FDA will approve MSC-based therapies for immune conditions when Phase 3 evidence meets the regulatory standard. MSC immunomodulation is a validated and approvable therapeutic mechanism within the FDA’s biologics framework. And the same biological properties that drove Ryoncil’s approval, including immune suppression, regulatory T-cell promotion, and macrophage polarization, are present in adipose-derived mesenchymal stem cells.
The ADSC autoimmune pipeline is working toward the same evidence standard in a broader range of conditions. Ryoncil is not the endpoint. It is the precedent. The 2018 MSC immunomodulation review covers the scientific continuity between the Ryoncil mechanism and the broader autoimmune application landscape.
Condition-by-Condition Evidence Review
Crohn’s Disease and Inflammatory Bowel Disease
Crohn’s disease has the most mature MSC evidence base of any autoimmune condition, driven in part by the use of allogeneic MSCs in perianal fistula, a specific Crohn’s complication, which led to the European approval of Alofisel (darvadstrocel) in 2018. For systemic Crohn’s and IBD more broadly, ADSC and MSC trials have reported reductions in disease activity indices and evidence of mucosal healing in Phase 1 and Phase 2 studies. The active Crohn’s trial pipeline on ClinicalTrials.gov spans multiple indications and cell sources, and Save My Fat’s overview of ADSC autoimmune and inflammatory research covers the indication landscape in more depth.
Multiple Sclerosis
MSC trials in multiple sclerosis have progressed through Phase 1 and Phase 2, with published data describing reductions in relapse rates, MRI lesion activity stabilization, and improvements in disability measures in relapsing-remitting MS patients. The 2019 MSC biology review covers the mechanistic basis for why immunomodulation matters in MS specifically, and the active multiple sclerosis MSC trial pipeline lists current recruiting studies.
The key consideration for MS patients evaluating banking is a timing one. Disease-related immune dysregulation and the systemic inflammation of active MS can affect autologous cell quality over time, and the 2018 MSC clinical review discusses this concern within the broader context of MSC therapy in chronic inflammatory disease. Banking earlier, before disease progression, preserves better quality cells for whatever pathway eventually becomes available.
Systemic Lupus Erythematosus
ADSC and MSC trials in systemic lupus erythematosus have reported reductions in disease activity scores, reductions in anti-dsDNA antibodies, and improvements in complement levels in Phase 1 and Phase 2 studies. The active lupus MSC trial pipeline covers multiple investigational approaches, and the 2018 MSC clinical review situates the lupus evidence base within the broader autoimmune category.
Rheumatoid Arthritis
Rheumatoid arthritis represents a natural intersection of the orthopedic and autoimmune evidence arcs, a joint disease driven by immune dysregulation. ADSC and MSC trials in rheumatoid arthritis have reported reductions in DAS28 disease activity scores, reductions in synovial inflammation markers, and favorable safety profiles in early-phase trials. The active adipose mesenchymal autoimmune trial pipeline on ClinicalTrials.gov includes rheumatoid arthritis among the recruiting studies, and the 2019 MSC biology review describes the mechanistic rationale in physician-appropriate depth.
Graft-Versus-Host Disease
This is the condition for which MSC therapy has the highest level of evidence and the first FDA approval. The approval of Ryoncil for steroid-refractory acute graft-versus-host disease, listed in the FDA approved products database, establishes the proof of concept for MSC-based immune therapy. Autologous ADSC banking in the context of graft-versus-host disease is less directly applicable than allogeneic therapy, because graft-versus-host disease itself is a complication of allogeneic stem cell transplant. What the approval provides for the broader autoimmune category is mechanism validation, not product substitution, and the 2018 MSC clinical review covers how the graft-versus-host disease evidence base supports the broader immune application landscape.
The Active Trial Pipeline
Active clinical trials investigating ADSC and MSC therapies for autoimmune and inflammatory conditions are recruiting now. The pipeline spans inflammatory bowel disease, multiple sclerosis, lupus, rheumatoid arthritis, and other immune conditions, and the searches across these indications together give patients and physicians a view of the current investigational landscape. The adipose mesenchymal autoimmune search covers the broad autoimmune category. Condition-specific searches including the Crohn’s MSC pipeline, the multiple sclerosis MSC pipeline, and the lupus MSC pipeline provide condition-focused detail. Save My Fat’s resources on finding legitimate clinical trials and what ClinicalTrials.gov phases mean help patients and physicians interpret what they find in the registry.
Banking Implications for Autoimmune Patients
The Timing Argument Is Stronger for Autoimmune Patients
For autoimmune patients, the case for banking earlier is more urgent than for healthy individuals. Active disease, systemic inflammation, immunosuppressive medication, and disease-related oxidative stress all affect ADSC biological quality over time. The cells banked during remission or early disease are typically higher quality than cells banked during active flares or after years of systemic inflammation, as the published MSC biology literature describes in its discussion of how cell function varies across health states. Save My Fat’s complete guide to banking covers the general timing rationale, and the same logic applies with added urgency to autoimmune patients specifically.
Autologous vs. Allogeneic: Why Banking Your Own Cells Matters
Most of the current ADSC autoimmune investigational protocols use autologous cells, meaning the patient’s own cells. Autologous therapy eliminates immune rejection risk, which is a meaningful consideration in patients whose immune systems are already dysregulated by their underlying condition. A patient who banks their own cells during relative health preserves the autologous starting material that autologous trial protocols and autologous expanded access pathways require, and the IFATS and ISCT joint consensus on adipose-derived cell characterization together with the 2018 MSC clinical review establish the biological rationale for why autologous sources matter in this context. Save My Fat’s overview of how banking works describes the banking process from the patient’s perspective.
Expanded Access as a Near-Term Pathway
For patients with serious autoimmune conditions who cannot wait for a trial or approval, expanded access is the formal FDA pathway for accessing investigational therapies. The Reagan-Udall Foundation’s Expanded Access Navigator is the recommended starting resource, and Save My Fat’s expanded access programs overview covers how banking relates to potential autologous ADSC expanded access requests. Expanded access is not a guaranteed pathway, but for patients with qualifying conditions who have exhausted standard options, it is worth evaluating alongside clinical trial enrollment and banking.
Evidence Summary Table
| Condition | Evidence Level | Key Signal | Active Trials |
|---|---|---|---|
| Graft-versus-host disease | Phase 3 RCT, FDA-approved (Ryoncil) | Day 28 response rate improvement | Limited, approval achieved |
| Crohn’s and perianal fistula | Phase 3 with EU approval (Alofisel), plus active ADSC trials | Fistula healing, disease activity reduction | Active recruiting |
| Multiple sclerosis | Phase 1 and 2 | Relapse rate reduction, MRI stabilization | Active recruiting |
| Systemic lupus | Phase 1 and 2 | SLEDAI reduction, antibody normalization | Active recruiting |
| Rheumatoid arthritis | Phase 1 and 2 | DAS28 reduction, synovial inflammation markers | Active recruiting |
The FDA approved products database, the 2018 MSC immunomodulation review, and the adipose mesenchymal autoimmune trial search together form the primary reference set for the evidence levels summarized in the table.
Frequently Asked Questions
Is Ryoncil an adipose-derived stem cell product?
No. Ryoncil is a bone-marrow-derived allogeneic MSC product manufactured by Mesoblast, approved by the FDA in December 2024 and listed in the FDA approved cellular and gene therapy products database. The relevance of its approval to ADSC autoimmune research is mechanistic rather than product-level. The immunomodulatory properties that drove Ryoncil’s approval are shared by adipose-derived mesenchymal stem cells. The approval validates the mechanism, not any specific adipose-derived product.
Should patients with active autoimmune disease bank their cells?
Banking during relative disease remission or early disease typically preserves better quality cells than banking during active inflammatory flares or after years of systemic immunosuppression, based on the published MSC biology literature describing how cell function varies with health state. The specific timing question is worth discussing with the treating physician, because the optimal window depends on disease severity, current medications, and projected disease trajectory. The general principle is that earlier banking preserves better options.
Can patients on immunosuppressive medications still bank?
This is a clinical question for the treating physician. Immunosuppressive medications primarily affect circulating immune cell populations, but the target cells for banking are adipose-derived stromal cells rather than circulating immune cells, and the direct impact of most immunosuppressive regimens on adipose-derived cell quality is not as clear-cut as the impact on circulating cells. A physician familiar with both the patient’s medication history and the banking protocol can advise on whether current medications affect harvest timing or cell characterization.
Are there active trials for my specific condition?
Active trials can be searched by condition on ClinicalTrials.gov. For autoimmune and inflammatory conditions specifically, the Crohn’s MSC trial search, the multiple sclerosis MSC trial search, and the lupus MSC trial search cover the three most commonly searched conditions. Save My Fat’s guide on finding legitimate clinical trials helps patients evaluate what they find in the registry.
What is the best first step for a patient with a serious autoimmune condition who wants to explore ADSC options?
Three parallel steps, all of which can be pursued in the same week rather than sequentially. First, search ClinicalTrials.gov for active recruiting trials in the specific condition. Second, use the Reagan-Udall Navigator to evaluate whether expanded access might be relevant given the specific condition severity and available alternatives. Third, consult with a Save My Fat provider about banking during the current disease state and discuss what banking would preserve for future pathways. These steps are not mutually exclusive, and the Save My Fat resource on expanded access programs covers the intersection of banking and the expanded access pathway in more depth.
Key Takeaways
MSC immunomodulation is a validated and FDA-approved therapeutic mechanism. Ryoncil’s December 2024 approval for graft-versus-host disease proved that MSC-based immune therapies can clear the full FDA pathway, and the regulatory precedent applies to the broader cell class rather than only to the specific approved product.
ADSCs share the immunomodulatory properties that drive MSC efficacy in immune conditions. The four core mechanisms (IDO and TGF-beta and PGE2 suppression of lymphocyte proliferation, regulatory T-cell promotion, natural killer cell suppression, and macrophage polarization toward the anti-inflammatory phenotype) are present across the MSC category and form the biological basis for active ADSC autoimmune trials.
Active ADSC and MSC trials are recruiting for Crohn’s disease, multiple sclerosis, lupus, rheumatoid arthritis, and other autoimmune conditions. The evidence base for autoimmune applications is earlier-stage than orthopedics but moving through Phase 2 across multiple conditions simultaneously, which is the pattern that typically precedes Phase 3 pivotal trials in cell therapy.
For autoimmune patients, the timing argument for banking is particularly strong. Active disease and systemic inflammation affect cell quality over time, and banking during remission or early disease preserves better biological material for whatever pathway eventually becomes available. The urgency is higher than for healthy individuals considering banking.
Autologous cell banking eliminates immune rejection risk, which is a meaningful consideration for patients whose immune systems are already dysregulated. Most current autoimmune investigational protocols use autologous cells, and banking during relative health preserves the autologous starting material those protocols require.
Expanded access through the Reagan-Udall Navigator is available for patients with serious conditions who cannot wait for trial enrollment or approval. Banking, clinical trial enrollment, and expanded access are three parallel pathways that can be evaluated simultaneously rather than sequentially for patients with autoimmune conditions that are progressing faster than the research pipeline.
Next Steps for Patients and Providers
Before taking any next step: adipose tissue banking is a preservation service for potential future use in FDA-regulated pathways, not a treatment or a guarantee of access to any specific clinical trial, therapy, or product. No ADSC-based therapy for Crohn’s disease, multiple sclerosis, lupus, rheumatoid arthritis, or any other autoimmune condition is FDA-approved, and banking cannot be represented to patients as a treatment for these conditions. Physicians considering partnership should independently verify applicable state licensing and informed-consent requirements, particularly in Florida, Utah, and Nevada, which have stem cell-specific statutes.
For patients with autoimmune conditions, the Save My Fat overviews of how banking works, ADSC autoimmune and inflammatory research, and expanded access programs together provide the research framework for evaluating banking in the context of a specific autoimmune condition. The adipose mesenchymal autoimmune trial search and the Reagan-Udall Foundation’s Expanded Access Navigator cover the two alternative access pathways.
For providers in rheumatology, gastroenterology, neurology, and internal medicine, the Save My Fat provider program overview and the partner sign-up page are the starting resources for adding banking as a service line that fits a practice already seeing autoimmune patients.
Save My Fat provides adipose tissue banking services in partnership with L2 Bio for laboratory operations. Save My Fat does not provide medical treatments, clinical trial enrollment, or Expanded Access services.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.
